Does absolute neutrophil count predict high tumor grade in African-American men with prostate cancer?

Prostate

Volumn 72, Issue 4, 2012, Pages 386-391

  Sadeghi, Neda ^a   Badalato, Gina M ^a   Hruby, Gregory ^a   Grann, Victor ^a   McKiernan, James M ^a  

^a Columbia University Medical Center ^*  (United States)

Author keywords

absolute neutrophil count; African American; prostate cancer; tumor grade

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; BENIGN ETHNIC NEUTROPENIA; CANCER GRADING; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

AFRICAN AMERICANS; AGED; CELL COUNT; COHORT STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEUTROPENIA; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84856042998     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21440     Document Type: Article

References (33)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010. p 23-35.
2. Caire AA, Sun L, Polascik TJ, Albala DM, Moul JW,. Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. BJU Int 2010; 106 (8): 1157-1160.
3. Gilbert SM, Benson MC, McKiernan JM,. Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population. Curr Urol Rep 2002; 3 (3): 189-193.
4. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M,. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. The Prostate 2011; 71 (5): 489-497.
5. Powell IJ, Zhou J, Sun Y, Sakr WA, Patel NP, Heilbrun LK, Everson RB,. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol 2004; 172 (5 Pt 1): 1848-1852. (Pubitemid 39363071)
6. Whitman EJ, Pomerantz M, Chen Y, Chamberlin MM, Furusato B, Gao C, Ali A, Ravindranath L, Dobi A, Sesterhenn IA, McLeod DG, Srivastava S, Freedman M, Petrovics G,. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev 2010; 19 (1): 1-8.
7. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, Greenway SC, Stram DO, Le Marchand L, Kolonel LN, Frasco M, Wong D, Pooler LC, Ardlie K, Oakley-Girvan I, Whittemore AS, Cooney KA, John EM, Ingles SA, Altshuler D, Henderson BE, Reich D,. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39 (5): 638-644. (Pubitemid 46676106)
8. Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, Catalona WJ,. Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. J Urol 2008; 179 (6): 2197-2201 (discussion 2202).
9. Kyle RA,. Natural history of chronic idiopathic neutropenia. N Engl J Med 1980; 302 (16): 908-909. (Pubitemid 10143990)
10. Grann VR, Bowman N, Joseph C, Wei Y, Horwitz MS, Jacobson JS, Santella RP, Hershman DL,. Neutropenia in 6 ethnic groups from the Caribbean and the U.S. Cancer 2008; 113 (4): 854-860.
11. Shoenfeld Y, Alkan ML, Asaly A, Carmeli Y, Katz M,. Benign familial leukopenia and neutropenia in different ethnic groups. Eur J Haematol 1988; 41 (3): 273-277.
12. Haddy TB, Rana SR, Castro O,. Benign ethnic neutropenia: What is a normal absolute neutrophil count? J Lab Clin Med 1999; 133 (1): 15-22. (Pubitemid 29032412)
13. Hsieh MM, Tisdale JF, Rodgers GP, Young NS, Trimble EL, Little RF,. Neutrophil count in African Americans: Lowering the target cutoff to initiate or resume chemotherapy? J Clin Oncol 2010; 28 (10): 1633-1637.
14. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP,. Prevalence of neutropenia in the U.S. population: Age, sex, smoking status, and ethnic differences. Ann Intern Med 2007; 146 (7): 486-492. (Pubitemid 351650557)
15. Grann VR, Ziv E, Joseph CK, Neugut AI, Wei Y, Jacobson JS, Horwitz MS, Bowman N, Beckmann K, Hershman DL,. Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean. Br J Haematol 2008; 143 (2): 288-293.
16. Addison CL, Belperio JA, Burdick MD, Strieter RM,. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 2004; 4: 28.
17. Wang J, Ou ZL, Hou YF, Luo JM, Shen ZZ, Ding J, Shao ZM,. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 2006; 25 (54): 7201-7211. (Pubitemid 44764189)
18. Shen H, Schuster R, Stringer KF, Waltz SE, Lentsch AB,. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J 2006; 20 (1): 59-64. (Pubitemid 43100476)
19. Elson J, Beebe-Dimmer J, Morgenstern H, Chilkuri M, Blanchard J, Lentsch A,. The Duffy Antigen/Receptor for Chemokines (DARC) and Prostate-Cancer Risk among Jamaican Men. Journal of Immigrant and Minority Health 2011; 13 (1): 36-41.
20. Karin M, Greten FR,. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5 (10): 749-759. (Pubitemid 41400849)
21. Dunn GP, Old LJ, Schreiber RD,. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21 (2): 137-148. (Pubitemid 39094044)
22. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011; 331 (6024): 1565-1570.
23. Souto JC, Vila L, Brú A,. Polymorphonuclear neutrophils and cancer: Intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev 2011; 31 (3): 311-363.
24. Cameron DJ,. A comparison of the cytotoxic potential in polymorphonuclear leukocytes obtained from normal donors and cancer patients. Clin Immunol Immunopathol 1983; 28 (1): 115-124. (Pubitemid 13056752)
25. Cameron DJ, Majeski JA,. Inhibition of macrophage-and neutrophil-mediated cytotoxicity by verapamil. J Surg Oncol 1988; 37 (1): 5-9. (Pubitemid 18040562)
26. Sanford MA, Yan Y, Canfield SE, Hassan W, Selleck WA, Atkinson G, Chen SH, Hall SJ,. Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer. Hum Gene Ther 2001; 12 (12): 1485-1498. (Pubitemid 34248285)
27. Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ,. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol 2006; 175 (6): 2087-2091. (Pubitemid 43668588)
28. Park SJ, Burdick MD, Brix WK, Stoler MH, Askew DS, Strieter RM, Mehrad B,. Neutropenia enhances lung dendritic cell recruitment in response to Aspergillus via a cytokine-to-chemokine amplification loop. J Immunol (Baltimore, Md: 1950) 2010; 185 (10): 6190-6197.
29. Bennouna S, Bliss SK, Curiel TJ, Denkers EY,. Cross-talk in the innate immune system: Neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J Immunol 2003; 171 (11): 6052-6058. (Pubitemid 37467225)
30. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z, Zhang J,. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006; 66 (12): 1311-1318. (Pubitemid 44384308)
31. Vindrieux D, Escobar P, Lazennec G,. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 2009; 16 (3): 663-673.
32. Zhang X, Majlessi L, Deriaud E, Leclerc C, Lo-Man R,. Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009; 31 (5): 761-771.
33. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ,. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (New York, NY) 2006; 8 (7): 578-586. (Pubitemid 44061313)